Annual Cash & Cash Equivalents
$76.91 M
-$29.53 M-27.74%
December 31, 2023
Summary
- As of February 7, 2025, RNAC annual cash & cash equivalents is $76.91 million, with the most recent change of -$29.53 million (-27.74%) on December 31, 2023.
- During the last 3 years, RNAC annual cash & cash equivalents has fallen by -$61.77 million (-44.54%).
- RNAC annual cash & cash equivalents is now -44.54% below its all-time high of $138.69 million, reached on December 1, 2020.
Performance
RNAC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$219.20 M
+$131.97 M+151.30%
September 1, 2024
Summary
- As of February 7, 2025, RNAC quarterly cash and cash equivalents is $219.20 million, with the most recent change of +$131.97 million (+151.30%) on September 1, 2024.
- Over the past year, RNAC quarterly cash and cash equivalents has increased by +$115.78 million (+111.95%).
- RNAC quarterly cash and cash equivalents is now at all-time high.
Performance
RNAC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RNAC Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -27.7% | +112.0% |
| 3 y3 years | -44.5% | +105.9% |
| 5 y5 years | +105.6% | +105.9% |
RNAC Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -32.6% | at low | at high | +185.0% |
| 5 y | 5-year | -44.5% | at low | at high | +267.0% |
| alltime | all time | -44.5% | +363.5% | at high | +1185.5% |
Cartesian Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $219.20 M(+151.3%) |
| Jun 2024 | - | $87.23 M(-15.7%) |
| Mar 2024 | - | $103.42 M(+34.5%) |
| Dec 2023 | $76.91 M(-27.7%) | $76.91 M(-3.4%) |
| Sep 2023 | - | $79.60 M(-28.9%) |
| Jun 2023 | - | $112.03 M(-11.0%) |
| Mar 2023 | - | $125.92 M(+18.3%) |
| Dec 2022 | $106.44 M(-6.7%) | - |
| Dec 2022 | - | $106.44 M(-5.7%) |
| Sep 2022 | - | $112.84 M(-18.3%) |
| Jun 2022 | - | $138.06 M(+21.7%) |
| Mar 2022 | - | $113.44 M(-0.5%) |
| Dec 2021 | $114.06 M(-17.8%) | $114.06 M(-0.5%) |
| Sep 2021 | - | $114.64 M(-8.8%) |
| Jun 2021 | - | $125.75 M(+0.3%) |
| Mar 2021 | - | $125.41 M(-9.6%) |
| Dec 2020 | $138.69 M | $138.69 M(-5.2%) |
| Sep 2020 | - | $146.26 M(+144.9%) |
| Jun 2020 | - | $59.73 M(-17.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $72.61 M(-19.2%) |
| Dec 2019 | $89.89 M(+140.3%) | $89.89 M(+162.6%) |
| Sep 2019 | - | $34.23 M(+13.4%) |
| Jun 2019 | - | $30.20 M(-6.1%) |
| Mar 2019 | - | $32.17 M(-14.0%) |
| Dec 2018 | $37.40 M(-47.1%) | $37.40 M(-25.9%) |
| Sep 2018 | - | $50.48 M(-16.2%) |
| Jun 2018 | - | $60.24 M(+3.3%) |
| Mar 2018 | - | $58.30 M(-17.5%) |
| Dec 2017 | $70.70 M(+20.5%) | $70.70 M(-2.0%) |
| Sep 2017 | - | $72.15 M(-12.7%) |
| Jun 2017 | - | $82.63 M(+210.2%) |
| Mar 2017 | - | $26.64 M(-54.6%) |
| Dec 2016 | $58.66 M(+81.4%) | $58.66 M(-1.4%) |
| Sep 2016 | - | $59.49 M(-28.0%) |
| Jun 2016 | - | $82.65 M(+384.7%) |
| Mar 2016 | - | $17.05 M(-47.3%) |
| Dec 2015 | $32.34 M(+94.9%) | $32.34 M |
| Dec 2014 | $16.59 M | - |
FAQ
- What is Cartesian Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cartesian Therapeutics?
- What is Cartesian Therapeutics annual cash & cash equivalents year-on-year change?
- What is Cartesian Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cartesian Therapeutics?
- What is Cartesian Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Cartesian Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of RNAC is $76.91 M
What is the all time high annual cash & cash equivalents for Cartesian Therapeutics?
Cartesian Therapeutics all-time high annual cash & cash equivalents is $138.69 M
What is Cartesian Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, RNAC annual cash & cash equivalents has changed by -$29.53 M (-27.74%)
What is Cartesian Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RNAC is $219.20 M
What is the all time high quarterly cash and cash equivalents for Cartesian Therapeutics?
Cartesian Therapeutics all-time high quarterly cash and cash equivalents is $219.20 M
What is Cartesian Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, RNAC quarterly cash and cash equivalents has changed by +$115.78 M (+111.95%)